BioMarin Pharma (BMRN) Misses Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NRIX
7. SUNS
8. OIG
9. SPY
10. SNDX

Go back to BioMarin Pharma (BMRN) Misses Q3 EPS by 2c

BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)

October 26, 2022 4:03 PM EDT

VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Between $140 Million and $170 MillionU.S. Biologics Application for ROCTAVIAN Accepted by U.S. Food and Drug Administration (FDA); Prescription Drug User Fee Act (PDUFA) Target Action Date is March 31, 2023; Commercial Launch of ROCTAVIAN Underway in the European Union (EU) Following August 24, 2022 Approval

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

Three Months Ended

September... More